CureVac N.V. (BIT:1CVAC)

Market Cap	1.03B
Revenue (ttm)	523.70M
Net Income (ttm)	180.66M
Shares Out	n/a
EPS (ttm)	0.80
PE Ratio	5.72
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	724
Open	4.752
Previous Close	4.752
Day's Range	4.752 - 4.752
52-Week Range	2.146 - 4.952
Beta	n/a
RSI	74.32
Earnings Date	Aug 15, 2025

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company’s portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, and cell membrane. In ad...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 983
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1CVAC